SCHEMBL2108029

SCHEMBL2108029

CC(C)(C)CC(C)(C)c1ccc(OCCCO)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.84
SMN1; SMN2 Q16637 3/20 0.84
SHBG P04278 1/20 0.52
HRH3 Q9Y5N1 5/20 0.48
HIF1A Q16665 4/20 0.48
LMNA P02545 4/20 0.48
USP2 O75604 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
APAF1 O14727 2/20 0.48
ALDH1A1 P00352 2/20 0.48
ERBB2 P04626 2/20 0.48
TP53 P04637 2/20 0.48
FYN P06241 2/20 0.48
CHRM2 P08172 2/20 0.48
CHRM4 P08173 2/20 0.48
CHRM5 P08912 2/20 0.48
ADRA2A P08913 2/20 0.48
MAPT P10636 2/20 0.48
HSPD1 P10809 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1592415 0.95 CYP3A4 (0.81) CYP3A4SMN1; SMN2SHBGHRH3HIF1A
Triton X SCHEMBL33822 0.91 CYP3A4 (1.00) CYP3A4SMN1; SMN2SHBGHRH3HIF1A
Triton X SCHEMBL21176032 0.91 CYP3A4 (1.00) CYP3A4SMN1; SMN2SHBGHRH3HIF1A
Triton X SCHEMBL15135853 0.88 CYP3A4 (0.93) CYP3A4SMN1; SMN2SHBGHRH3HIF1A
Triton X SCHEMBL5933893 0.88 CYP3A4 (0.93) CYP3A4SMN1; SMN2SHBGHRH3HIF1A
SCHEMBL2961794 0.85 CYP3A4 (0.82) CYP3A4SMN1; SMN2SHBGHRH3HIF1A
SCHEMBL13932430 0.85 CYP3A4 (0.82) CYP3A4SMN1; SMN2SHBGHRH3HIF1A
SCHEMBL16198907 0.85 CYP3A4 (0.82) CYP3A4SMN1; SMN2SHBGHRH3HIF1A
SCHEMBL20168125 0.85 CYP3A4 (0.82) CYP3A4SMN1; SMN2SHBGHRH3HIF1A
SCHEMBL1091879 0.85 CYP3A4 (0.82) CYP3A4SMN1; SMN2SHBGHRH3HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158088-B2 Extractant compositions for co-extracting cesium and strontium, a method of separating cesium and strontium from an aqueous feed, and calixarene compounds BATTELLE ENERGY ALLIANCE, LLC (US) 2012-04-17 US claimed
US-20100116749-A1 EXTRACTANT COMPOSITIONS FOR CO EXTRACTING CESIUM AND STRONTIUM, A METHOD OF SEPARATING CESIUM AND STRONTIUM FROM AN AQUEOUS FEED, CALIXARENE COMPOUNDS, AND AN ALCOHOL MODIFIER UT-BATTELLE, LLC 2010-05-13 US claimed
US-6174503-B1 NUCLEAR WASTES TREATMENT, ESPECIALLY WASTES WITH A HIGH CONCENTRATION OF COMPETING ALKALI METAL CATIONS LOCKHEED MARTIN ENERGY RESEARCH CORPORATION 2001-01-16 US claimed
US-20230212662-A1 DEVELOPMENT OF NOVEL DETERGENTS FOR USE IN PCR SYSTEMS Life Technologies Corporation 2023-07-06 US disclosed
US-8270554-B2 Methods of producing cesium-131 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) 2012-09-18 US disclosed
US-8158088-B2 Extractant compositions for co-extracting cesium and strontium, a method of separating cesium and strontium from an aqueous feed, and calixarene compounds BATTELLE ENERGY ALLIANCE, LLC (US) 2012-04-17 US disclosed
US-8158088-B2 Extractant compositions for co-extracting cesium and strontium, a method of separating cesium and strontium from an aqueous feed, and calixarene compounds BATTELLE ENERGY ALLIANCE, LLC (US) 2012-04-17 US disclosed
US-20100296616-A1 METHODS OF PRODUCING CESIUM-131 BATTELLE ENERGY ALLIANCE, LLC (US) 2010-11-25 US disclosed
US-20100116749-A1 EXTRACTANT COMPOSITIONS FOR CO EXTRACTING CESIUM AND STRONTIUM, A METHOD OF SEPARATING CESIUM AND STRONTIUM FROM AN AQUEOUS FEED, CALIXARENE COMPOUNDS, AND AN ALCOHOL MODIFIER UT-BATTELLE, LLC 2010-05-13 US disclosed
US-20100116749-A1 EXTRACTANT COMPOSITIONS FOR CO EXTRACTING CESIUM AND STRONTIUM, A METHOD OF SEPARATING CESIUM AND STRONTIUM FROM AN AQUEOUS FEED, CALIXARENE COMPOUNDS, AND AN ALCOHOL MODIFIER UT-BATTELLE, LLC 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100116749-A1 EXTRACTANT COMPOSITIONS FOR CO EXTRACTING CESIUM AND STRONTIUM, A METHOD OF SEPARATING CESIUM AND STRONTIUM FROM AN AQUEOUS FEED, CALIXARENE COMPOUNDS, AND AN ALCOHOL MODIFIER CANX, CBX6, CALD1 CYP3A4 659/4885SMN1; SMN2 2527/4885SHBG 2044/4885
US-20230212662-A1 DEVELOPMENT OF NOVEL DETERGENTS FOR USE IN PCR SYSTEMS POLRMT, ABHD16A, PLD3 CYP3A4 3514/4885SMN1; SMN2 2906/4885SHBG 4735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.